全文获取类型
收费全文 | 1555篇 |
免费 | 93篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 79篇 |
妇产科学 | 28篇 |
基础医学 | 165篇 |
口腔科学 | 22篇 |
临床医学 | 185篇 |
内科学 | 379篇 |
皮肤病学 | 42篇 |
神经病学 | 77篇 |
特种医学 | 365篇 |
外国民族医学 | 1篇 |
外科学 | 70篇 |
综合类 | 44篇 |
预防医学 | 78篇 |
眼科学 | 29篇 |
药学 | 129篇 |
中国医学 | 1篇 |
肿瘤学 | 64篇 |
出版年
2023年 | 4篇 |
2022年 | 8篇 |
2021年 | 14篇 |
2020年 | 16篇 |
2019年 | 13篇 |
2018年 | 20篇 |
2017年 | 9篇 |
2016年 | 31篇 |
2015年 | 33篇 |
2014年 | 29篇 |
2013年 | 44篇 |
2012年 | 37篇 |
2011年 | 54篇 |
2010年 | 52篇 |
2009年 | 57篇 |
2008年 | 38篇 |
2007年 | 84篇 |
2006年 | 38篇 |
2005年 | 64篇 |
2004年 | 27篇 |
2003年 | 18篇 |
2002年 | 16篇 |
2001年 | 20篇 |
2000年 | 26篇 |
1999年 | 25篇 |
1998年 | 92篇 |
1997年 | 98篇 |
1996年 | 104篇 |
1995年 | 65篇 |
1994年 | 67篇 |
1993年 | 64篇 |
1992年 | 10篇 |
1991年 | 32篇 |
1990年 | 29篇 |
1989年 | 49篇 |
1988年 | 42篇 |
1987年 | 51篇 |
1986年 | 30篇 |
1985年 | 48篇 |
1984年 | 21篇 |
1983年 | 20篇 |
1982年 | 25篇 |
1981年 | 23篇 |
1980年 | 31篇 |
1979年 | 9篇 |
1978年 | 11篇 |
1977年 | 16篇 |
1976年 | 26篇 |
1975年 | 16篇 |
1970年 | 2篇 |
排序方式: 共有1762条查询结果,搜索用时 15 毫秒
61.
62.
63.
S Wurtzer V Marechal JM Mouchel Y Maday R Teyssou E Richard JL Almayrac L Moulin 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2020,25(50)
IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease (COVID-19). People infected with SARS-CoV-2 may exhibit no or mild non-specific symptoms; thus, they may contribute to silent circulation of the virus among humans. Since SARS-CoV-2 RNA can be detected in stool samples, monitoring SARS-CoV-2 RNA in waste water (WW) has been proposed as a complementary tool to investigate virus circulation in human populations.AimTo test if the quantification of SARS-CoV-2 genomes in WW correlates with the number of symptomatic or non-symptomatic carriers.MethodWe performed a time-course quantitative analysis of SARS-CoV-2 by RT-qPCR in raw WW samples collected from several major WW treatment plants in Greater Paris. The study period was 5 March to 23 April 2020, including the lockdown period in France (from 17 March).ResultsWe showed that the increase of genome units in raw WW accurately followed the increase of human COVID-19 cases observed at the regional level. Of note, the viral genome could be detected before the epidemic grew massively (around 8 March). Equally importantly, a marked decrease in the quantities of genome units was observed concomitantly with the reduction in the number of new COVID-19 cases, 29 days following the lockdown.ConclusionThis work suggests that a quantitative monitoring of SARS-CoV-2 genomes in WW could generate important additional information for improved monitoring of SARS-CoV-2 circulation at local or regional levels and emphasises the role of WW-based epidemiology. 相似文献
64.
65.
Philippe Grandjean Latifa Abdennebi‐Najar Robert Barouki Carl F. Cranor Ruth A. Etzel David Gee Jerrold J. Heindel Karin S. Hougaard Patricia Hunt Tim S. Nawrot Gail S. Prins Beate Ritz Morando Soffritti Jordi Sunyer Pal Weihe 《Basic & clinical pharmacology & toxicology》2019,125(Z3):70-80
Much progress has happened in understanding developmental vulnerability to preventable environmental hazards. Along with the improved insight, the perspective has widened, and developmental toxicity now involves latent effects that can result in delayed adverse effects in adults or at old age and additional effects that can be transgenerationally transferred to future generations. Although epidemiology and toxicology to an increasing degree are exploring the adverse effects from developmental exposures in human beings, the improved documentation has resulted in little progress in protection, and few environmental chemicals are currently regulated to protect against developmental toxicity, whether it be neurotoxicity, endocrine disruption or other adverse outcome. The desire to obtain a high degree of certainty and verification of the evidence used for decision‐making must be weighed against the costs and necessary duration of research, as well as the long‐term costs to human health because of delayed protection of vulnerable early‐life stages of human development and, possibly, future generations. Although two‐generation toxicology tests may be useful for initial test purposes, other rapidly emerging tools need to be seriously considered from computational chemistry and metabolomics to CLARITY‐BPA‐type designs, big data and population record linkage approaches that will allow efficient generation of new insight; epigenetic mechanisms may necessitate a set of additional regulatory tests to reveal such effects. As reflected by the Prenatal Programming and Toxicity (PPTOX) VI conference, the current scientific understanding and the timescales involved require an intensified approach to protect against preventable adverse health effects that can harm the next generation and generations to come. While further research is needed, the main emphasis should be on research translation and timely public health intervention to avoid serious, irreversible and perhaps transgenerational harm. 相似文献
66.
Per Damkier Dorte Lassen Mette Marie Hougaard Christensen Kenneth Grnkjr Madsen Maja Hellfritzsch Anton Pottegrd 《Basic & clinical pharmacology & toxicology》2019,124(1):28-31
Delta‐9‐tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9. Consequently, cannabis use might infer a risk of drug‐drug interaction with substrates for this enzyme, which includes drugs known to have a narrow therapeutic window. In this study, we describe a case report of a 27‐year‐old man treated with warfarin due to mechanical heart valve replacement who presented with elevated international normalized ratio (INR) value (INR = 4.6) following recreational cannabis use. We conducted a review of the available literature, using the PubMed and EMBASE databases while following PRISMA guidelines. Following screening of 85 articles, three eligible articles were identified, including one in vitro study and two case reports. The in vitro study indicated that THC inhibits the CYP2C9‐mediated metabolism of warfarin. One case study reported of a man who on two occasions of increased marijuana use experienced INR values above 10 as well as bleeding. The other case study reported of a patient who initiated treatment with a liquid formulation of cannabidiol for the management of epilepsy, ultimately necessitating a 30% reduction in warfarin dose to maintain therapeutic INR values. The available, although sparse, data suggest that use of cannabinoids increases INR values in patients receiving warfarin. Until further data are available, we suggest patients receiving warfarin be warned against cannabis use. 相似文献
67.
68.
69.
T. Schuetze V. Nørholm L. Raabæk Olsen H. Hougaard M. Ekstrøm P. Wagn P. Bech 《Nordic journal of psychiatry》2013,67(2):119-122
Depressive symptoms within the range of schizophrenic syndromes constitute a major diagnostic and therapeutic problem. Earlier research has indicated that available depression scales are not adequate when examining mood disturbances in patients with schizophrenia. We have made an attempt to estimate the reliability and validity of the Danish version of the Calgary Depression Scale for Schizophrenia. The external validity has been analysed in relation to the Major Depression Inventory (MDI). The internal validity has been analysed by using Loevinger's coefficient of homogeneity as the primary statistic. For the inter-observer reliability the intra-class coefficients have been calculated. It was shown that a subscale of the Calgary scale has sufficient reliability and validity. 相似文献
70.
Stephania Donayre Pimentel Heather Adams Tamara Ellis Robin Clark Craig Sully Catherine Paré Michael JL. Sullivan 《Journal of traumatic stress》2020,33(5):731-740
Catastrophizing has been discussed as a cognitive precursor to the emergence of posttraumatic stress disorder (PTSD) symptoms following the experience of stressful events. Implicit in cognitive models of PTSD is that treatment-related reductions in catastrophizing should yield reductions in PTSD symptoms. The tenability of this prediction has yet to be tested. The present study investigated the sequential relation between changes in a specific form of catastrophizing—symptom catastrophizing—and changes in PTSD symptom severity in a sample of 73 work-disabled individuals enrolled in a 10-week behavioral activation intervention. Measures of symptom catastrophizing and PTSD symptom severity were completed at pre-, mid-, and posttreatment assessment points. Cross-sectional analyses of pretreatment data revealed that symptom catastrophizing accounted for significant variance in PTSD symptom severity, β = .40, p < .001, sr = .28 (medium effect size), even when controlling for known correlates of symptom catastrophizing, such as pain and depression. Significant reductions in symptom catastrophizing and PTSD symptoms were observed during treatment, with large effect sizes, ds = 1.42 and 0.94, respectively, ps < .001. Cross-lagged analyses revealed that early change in symptom catastrophizing predicted later change in PTSD symptoms; early changes in PTSD symptom severity did not predict later change in symptom catastrophizing. These findings are consistent with the conceptual models that posit a causal relation between catastrophizing and PTSD symptom severity. The clinical implications of the findings are discussed. 相似文献